Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03733743
Other study ID # NL64753.068.18
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 9, 2018
Est. completion date March 29, 2019

Study information

Verified date September 2018
Source Maastricht University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the existence of a day-night rhythm in skeletal muscle energy metabolism in prediabetic subjects. Subjects will stay at the research facility for 44 hours with a standardized living protocol during which several measurements of skeletal muscle and whole body energy metabolism will be performed.


Description:

Recent evidence from both observational and experimental studies indicates that disobedience of a normal day-night rhythm negatively influences metabolic and cardiovascular health, possibly leading to obesity and type 2 diabetes mellitus (T2DM). An important hallmark of obesity and T2DM is a decreased skeletal muscle mitochondrial function. Interestingly, recent research indicates that also skeletal muscle mitochondrial function is under the influence of a day-night rhythm. In this study, the presence of a day-night rhythm in skeletal muscle energy metabolism (in particular mitochondrial function) of overweight prediabetic participants will be investigated. During this study, subjects will stay at the research unit for 44 hours, with standardized meals and sleeping time. Five muscle biopsies (v. lateralis) and frequent blood draws will be taken. In addition, indirect calorimetry measurements will be performed.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date March 29, 2019
Est. primary completion date March 20, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 40 Years to 75 Years
Eligibility Inclusion criteria:

- Caucasian

- Healthy (as determined by dependent physician)

- Overweight: BMI 25 - 35 kg/m2

- Prediabetic based on one or a combination of the following criteria:

- Impaired Glucose Tolerance (IGT): plasma glucose values = 7.8 mmol/l and = 11.1 mmol/l 120 minutes after glucose drink consumption during OGTT in screening.

- Impaired Fasting Glucose (IFG): Fasting plasma glucose = 6.1 mmol/l and = 6.9 mmol/l.

- Insulin Resistance: glucose clearance rate = 360ml/kg/min, as determined using the OGIS120 model.

- HbA1c of 5.7-6.4%.

- Regular sleeping time (normally 7 - 9h daily)

- Stable dietary habits: no weight gain or loss > 3kg in the last three months.

Exclusion criteria:

- Use of anticoagulants

- Previously diagnosed with type 2 diabetes

- Current alcohol consumption > 20 grams alcohol/day

- Extreme early bird or extreme night person (score = 30 or = 70 on MEQ-SA questionnaire)

- Heavily varying sleep-wake rhythm

- Nightshift work during last 3 months

- Travel across > 1 time zone in the last 3 months

- Significant food allergies/intolerance (seriously hampering study meals)

- Using > 400mg caffeine daily (more than 4 coffee or energy drink)

- Smoking

Study Design


Intervention

Other:
Standardized living protocol
Subjects stay at the research facility for 44 hours and adhere to a standard sleeping, eating and activity protocol. During this protocol, multiple measurements will be performed including skeletal muscle biopsies (m. vastus lateralis), blood draws, indirect calorimetry and MRS measurements.

Locations

Country Name City State
Netherlands Maastricht University Maastricht Limburg

Sponsors (2)

Lead Sponsor Collaborator
Maastricht University Maastricht University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Day-night rhythm in skeletal muscle mitochondrial respiration O2-flux (pmol/mg/s) measured with high resolution respirometry measured on day two at 8:00, 13:00, 18:00, 23:00, 04:00
Secondary Day-night rhythm in whole-body energy metabolism (energy expenditure) Energy expenditure (kJ/min) measured by indirect calorimetry measured on day two at 8:00, 13:00, 18:00, 23:00, 04:00
Secondary Day-night rhythm in whole-body energy metabolism (glucose oxidation) glucose oxidation (g/min) measured by indirect calorimetry measured on day two at 8:00, 13:00, 18:00, 23:00, 04:00
Secondary Day-night rhythm in whole-body energy metabolism (fat oxidation) fat oxidation (g/min) measured by indirect calorimetry measured on day two at 8:00, 13:00, 18:00, 23:00, 04:00
Secondary Day-night rhythm in muscle protein levels of markers involved in molecular clock and mitochondrial metabolism. Quantify protein levels by Western blots measured on day two at 8:00, 13:00, 18:00, 23:00, 04:00
Secondary Day-night rhythm in muscle DNA of markers involved in molecular clock and mitochondrial metabolism. Quantify DNA by qPCR measured on day two at 8:00, 13:00, 18:00, 23:00, 04:00
Secondary Day-night rhythm in muscle DNA involved in molecular clock and mitochondrial metabolism. Quantify DNA by micro-array measured on day two at 8:00, 13:00, 18:00, 23:00, 04:00
Secondary Day-night rhythm in muscle mRNA markers involved in molecular clock and mitochondrial metabolism. Quantify mRNA levels by micro array measured on day two at 8:00, 13:00, 18:00, 23:00, 04:00
Secondary Day-night rhythm of markers of normal day-night rhythm (cortisol) Blood cortisol levels measured on day two, every two hours for 24 hours beginning at 08:00
Secondary Day-night rhythm of in markers of normal day-night rhythm (core body temperature) Core body temperature measured by an ingested telemetric pill. measured continuously for 24 hours on day two
Secondary Day-night rhythm of in markers of normal day-night rhythm (melatonin) Blood melatonin levels. measured on day two, every two hours for 24 hours beginning at 08:00
Secondary Day-night rhythm in serum glucose Serum glucose levels determined from venous blood draws measured on day two, every two hours for 24 hours beginning at 08:00
Secondary Day-night rhythm in serum insulin Serum insulin levels determined from venous blood draws measured on day two, every two hours for 24 hours beginning at 08:00
Secondary Day-night rhythm in serum free fatty acids (FFA) Serum FFA levels determined from venous blood draws measured on day two, every two hours for 24 hours beginning at 08:00
Secondary Day-night rhythm in serum triglycerides Serum triglyceride levels determined from venous blood draws measured on day two, every two hours for 24 hours beginning at 08:00
Secondary Day-night rhythm in serum cholesterol Serum cholesterol levels determined from venous blood draws measured on day two, every two hours for 24 hours beginning at 08:00
Secondary Change in energy status of the heart between morning and evening variation in phosphorus metabolites measured by Magnetic Resonance Imaging and - Spectroscopy (MRI/MRS) Measured on first study day 5:30 PM (duration 45 minutes), second study day 7:30 AM (duration 45 minutes)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2